Enliven Therapeutics moves ELVN-001 closer to Phase 3 as CML drug competition intensifies
Find out how Enliven Therapeutics’ ELVN-001 data and FDA alignment could reshape chronic myeloid leukemia drug development.
Pharma & Biotech